Heron Sues Viatris to Block Copies of Revenue-Driver Cinvanti

Heron Therapeutics Inc. alleges in a new lawsuit that a generic version of Cinvanti proposed by Viatris Inc. unit Mylan Pharmaceuticals Inc. infringes nine patents for the injection, which treats nausea and vomiting from cancer chemotherapy and accounts for most of Heron’s revenue.

Mylan wants to sell a generic version of Cinvanti’s injectable emulsion containing 130 milligrams of the drug’s active ingredient, aprepitant, per 18 milliliters, according to a complaint filed Sept. 15 in the US District Court for the District of Delaware.

The US Food and Drug Administration approved the Cinvanti emulsion in November 2017, the suit says. The ...